Complement receptors and regulatory proteins in human atherosclerotic lesions.

Arteriosclerosis : an Official Journal of the American Heart Association, Inc
P S Seifert, G K Hansson

Abstract

Complement activation in human atherosclerotic lesions is indicated by the presence of C5b-9 terminal complexes. By using monoclonal antibodies to the complement C3b receptor (CR1) and the iC3b receptor (CR3), it was observed that approximately 20% of the cells in complicated human carotid lesions express CR1 and CR3 antigens. One to five percent of complement receptor-positive cells stained for smooth muscle cell-specific myosin, and the remainder were determined to be predominantly macrophages, based on their reactivity to anti-LeuM3 (CD14) monoclonal antibody. No C3dg receptor (CR2)-positive cells were observed in any of the eight lesions examined. The complement regulatory glycoprotein decay accelerating factor (DAF) was widely distributed extracellularly, in addition to being present on 20% to 60% of the total cell population. Factor H, a plasma protein that regulates alternative pathway C3 convertase formation, was observed extracellularly in 70% of the lesions examined. C1 inhibitor was present in a few plaque specimens, was relatively sparse, and appeared largely cell associated. Terminal C5b-9 complement complexes were pervasive in all lesions. Both the complement regulatory proteins and the activation products were li...Continue Reading

References

May 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·W P Kolb, H J Müller-Eberhard
Nov 2, 1976·The Journal of Experimental Medicine·K Whaley, S Ruddy
Oct 1, 1975·The Journal of Experimental Medicine·D T Fearon, K F Austen
Jan 1, 1986·The Journal of Experimental Medicine·A S AschV Nussenzweig
Mar 1, 1986·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·L JonassonG K Hansson
Oct 1, 1988·Atherosclerosis·P S Seifert, M D Kazatchkine
Feb 1, 1988·Scandinavian Journal of Immunology·T E Mollnes, P J Lachmann
Apr 1, 1988·Experimental and Molecular Pathology·P S SeifertW J Dodds
Jun 1, 1987·Experimental Cell Research·G K HanssonM Heideman
Feb 20, 1986·The New England Journal of Medicine·R Ross
Feb 15, 1985·The Biochemical Journal·A C Yeung LaiwahK Whaley
Jan 1, 1983·Annual Review of Immunology·D T Fearon, W W Wong
Jan 1, 1983·Springer Seminars in Immunopathology·R J Ziccardi
Jan 1, 1981·Annual Review of Biochemistry·K B Reid, R R Porter

❮ Previous
Next ❯

Citations

Aug 15, 1996·Clinica Chimica Acta; International Journal of Clinical Chemistry·A SarríaM Bueno
Jan 1, 1995·Immunology Today·G WickQ Xu
Oct 28, 1999·American Heart Journal·A NicolettiG K Hansson
Jul 25, 1997·Atherosclerosis·J TorzewskiC Fitzsimmons
Aug 7, 1998·Atherosclerosis·F MachP Libby
Mar 4, 2000·Molecular Immunology·F Niculescu, H Rus
Oct 3, 2002·Cardiovascular Surgery : Official Journal of the International Society for Cardiovascular Surgery·R S A Lord, Y V Bobryshev
Dec 12, 2001·Trends in Immunology·G WickG Millonig
Apr 13, 2000·Journal of Internal Medicine·A NicolettiG K Hansson
Oct 23, 2009·The New England Journal of Medicine·Marina Noris, Giuseppe Remuzzi
Jan 31, 1995·Proceedings of the National Academy of Sciences of the United States of America·W PalinskiJ L Witztum
Dec 22, 1999·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·E BalslevP Garred
Dec 1, 1995·The Journal of Clinical Investigation·G SchettG Wick
Sep 3, 1998·The Journal of Clinical Investigation·A NicolettiG K Hansson
Aug 27, 2009·Biologics : Targets & Therapy·Prathit A Kulkarni, Vahid Afshar-Kharghan
Jul 3, 2010·Clinical Journal of the American Society of Nephrology : CJASN·Marina NorisGiuseppe Remuzzi
Jul 28, 2012·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Jan MachalJiri Vitovec
Apr 23, 2004·Expert Opinion on Biological Therapy·Xinghua Zhou, Göran K Hansson
Sep 25, 2014·Frontiers in Pediatrics·Johannes HoferThomas Giner
Mar 23, 2004·Annual Review of Immunology·Georg WickQingbo Xu
Feb 13, 2017·The Medical Clinics of North America·Joseph J Shatzel, Jason A Taylor
May 9, 2001·Lupus·P A GordonY Shoenfeld
Apr 17, 2010·Angiology·Dayangku Fatiha Pengiran BurutGordon A A Ferns
Jan 9, 2001·Arteriosclerosis, Thrombosis, and Vascular Biology·X ZhouG K Hansson
Oct 1, 1995·Arteriosclerosis, Thrombosis, and Vascular Biology·W PalinskiJ L Witztum
Jan 1, 1996·Arteriosclerosis, Thrombosis, and Vascular Biology·J R Guyton, K F Klemp
May 18, 2005·Hypertension·Alejandro R ChadeLilach O Lerman
Mar 1, 1997·Arteriosclerosis, Thrombosis, and Vascular Biology·B MetzlerG Wick
Sep 23, 2006·Arteriosclerosis, Thrombosis, and Vascular Biology·Göran K Hansson
Jun 21, 2015·Immunologic Research·Sonia I VlaicuHorea Rus

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.